Jarden says a range of outcomes possible for Pacific Edge

(Image: Pacific Edge)
Pacific Edge has bought time to overturn a decision that would have seen Medicare coverage of Cxbladder cease in the US on July 17, but a range of outcomes are still possible, said Jarden.The investment house rates the stock at neutral with a 12-month target price of 16 cents. That view is based on “an equal weighting of Pacific Edge executing a survival workstream that requires investment in further evidence and with further equity support required and the other where this proves too difficult and Pacific Edge elects to wind down&rd...
Subscribe to BusinessDesk
Stay informed on business, government and financial developments across New Zealand.
- Deeply researched, twice-edited and fact-checked news
- Annual subscribers also receive a complimentary subscription to The Wall Street Journal
- Personalised email news alerts, plus gift up to 5 stories a month to non-subscribers
You can cancel anytime with two clicks, an email or a phone call.
Find out
more.
We are serious about journalism.
Not convinced yet?
Subscribe to our free 7am Headlines newsletter.
A quick summary of everything BusinessDesk has published in the previous 24 hours. No BusinessDesk
subscription needed.